Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

<< Previous

Bullboard Posts

Next >>

Post by jg75123on Dec 14, 2020 12:23pm

145 Views

Post# 32100267

HOLL just posted $40M in revenues. market cap is $60m

Hollister Biosciences 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone (CNW Group/Hollister Biosciences Inc.)

Hollister also reports that Venom generated CDN$ 4.8 million in adjusted EBITDA over the same period

Market needs to wake up to this one.

HOLL

thank me later

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features